This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare. This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Ampiroxicam, Ibuprofen, Etodolac, Naproxen, Piroxicam (oral dosage form), Flurbiprofen (oral dosage form), Flurbiprofen axetil, Loxoprofen sodium hydrate (oral dosage form), Lornoxicam

October 8, 2024

Therapeutic category

Antipyretics, analgesics and anti-inflammatory agents

Non-proprietary name

Ampiroxicam

Ibuprofen

Etodolac

Naproxen

Piroxicam (oral dosage form)

Flurbiprofen (oral dosage form)

Flurbiprofen axetil

Loxoprofen sodium hydrate (oral dosage form)

Lornoxicam

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revised
9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC	9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC
BACKGROUNDS	BACKGROUNDS
9.5 Pregnant Women	9.5 Pregnant Women
Pregnant women (excluding the third trimester) or women who may	Pregnant women (excluding the third trimester) or women who may
be pregnant	be pregnant
This drug should be administered only when the therapeutic benefits	This drug should be administered only when the therapeutic benefits
are considered to outweigh the risks. If administration is deemed	are considered to outweigh the risks. If administration is deemed
necessary, caution should be exercised such as limiting the drug to	necessary, caution should be exercised such as limiting the drug to
the minimum effective use and checking amniotic fluid volume as	the minimum effective use and checking amniotic fluid volume <u>and</u>
necessary. Renal impairment and decreased urine output in	findings suggestive of constriction of the foetal ductus arteriosus
foetuses as well as accompanying oligohydramnios have been	with consideration given to the gestational age and duration of
reported following use of cyclooxygenase inhibitors (oral dosage	administration as necessary. Renal impairment and decreased urine
form or suppository) in pregnant women.	output in foetuses as well as accompanying oligohydramnios have
	been reported following use of cyclooxygenase inhibitors (oral
	dosage form or suppository) in pregnant women. <u>It has been</u>
	reported that constriction of the foetal ductus arteriosus occurred in
	pregnant women who had been administered cyclooxygenase
	inhibitors (preparations with expected systemic effects) in their
	second trimester of pregnancy.
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
(N/A)	Myocardial infarction, cerebrovascular disorder
	Cardiovascular thromboembolic events including myocardial

	infarction and cerebrovascular disorder may occur.

(Reference) Summary of Study Results Using National Database of Health Insurance Claims and Specific Health Checkup of Japan (NDB)

(Evaluation of the risk of cardiovascular events due to non-steroidal anti-inflammatory drugs using NDB)

https:// www.pmda.go.jp/files/000270715.pdf

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.